Medicine and Dentistry
Acute Myeloid Leukemia
95%
COVID-19
68%
Acute Promyelocytic Leukemia
47%
Hematologic Malignancy
39%
Minimal Residual Disease
34%
Overall Survival
33%
Diffuse Large B-Cell Lymphoma
31%
Decitabine
30%
Infection
27%
Disease
27%
Arsenic Trioxide
23%
Tretinoin
21%
Reverse Transcription Polymerase Chain Reaction
20%
Flow Cytometry
17%
Myelodysplastic Syndrome
17%
Nucleophosmin
17%
DNA Damage
17%
Hematology
16%
Rituximab
16%
Clinical Trial
16%
Lymphocyte
16%
Granulocyte
15%
Prematurity
15%
Molecular Diagnosis
15%
Pemphigus vulgaris
15%
Splenic Marginal Zone Lymphoma
15%
Capillary Electrophoresis
15%
NPM1
15%
Phagocytosis
15%
B Cell
13%
Mitochondrial Respiration
13%
Anthracycline
13%
Leukemia
13%
Monoclonal Antibody
12%
Mortality Rate
12%
Diagnosis
12%
Hypomethylating Agent
11%
CHOP
11%
Hematopoietic Stem Cell
11%
Cell Transplantation
11%
CD20
11%
Acute Leukemia
9%
Chronic Myelogenous Leukemia
9%
Cancer Cell
9%
Hepatitis C
9%
Homeostasis
9%
Neoplasm
9%
Multiple Myeloma
8%
Acute Myelogenous Leukemia
8%
Prednisone
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Promyelocytic Leukemia
57%
Hematologic Malignancy
50%
Disease
46%
Diffuse Large B Cell Lymphoma
44%
Infection
42%
Chemotherapy
39%
Overall Survival
36%
Remission
35%
Arsenite
25%
Minimal Residual Disease
24%
Nucleophosmin
22%
Retinoic Acid
22%
Rituximab
19%
Leukemia
18%
Comorbidity
18%
Myelodysplastic Syndrome
18%
Mortality Rate
18%
Coronavirinae
17%
Clinical Trial
16%
Prematurity
15%
Antiapoptotic
15%
Decitabine
15%
Alemtuzumab
15%
Anthracycline
14%
Vaccination Policy
14%
Flow Cytometry
13%
Monoclonal Antibody
12%
Malignant Neoplasm
11%
Acute Leukemia
10%
Adavosertib
10%
Mitoxantrone
10%
Prednisone
10%
Chronic Lymphatic Leukemia
10%
Multiple Sclerosis
9%
SARS Coronavirus
9%
6 Diazo 5 Oxonorleucine
8%
Bispecific Antibody
7%
Hepatitis C
7%
Phosphatidylinositol 4 Phosphate Kinase
7%
Cytotoxicity
7%
Intercellular Adhesion Molecule 1
7%
Estrogen Receptor Beta
7%
Buformin
7%
Splenic Marginal Zone Lymphoma
7%
Ascorbic Acid
7%
Dysproteinemia
7%
Immunoblastic Lymphadenopathy
7%
Pemphigus vulgaris
7%
Nirmatrelvir
7%
Keyphrases
Acute Myeloid Leukemia
99%
COVID-19
38%
Leukemia Patients
33%
Minimal Residual Disease
33%
Older Patients
29%
Acute Promyelocytic Leukemia
25%
Decitabine
22%
Hematology
17%
Overall Survival
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
15%
Pemphigus Vulgaris
15%
Adult Acute Lymphoblastic Leukemia
15%
Molecular Diagnostics
15%
Nucleophosmin 1 (NPM1)
15%
B-cell Lymphoma 2 (Bcl-2)
15%
Flow Cytometry
13%
Myelodysplastic Syndrome
12%
Chemotherapy
11%
Rituximab
10%
Prognostic Relevance
10%
COVID-19 Infection
10%
Comorbidity
10%
All-trans Retinoic Acid
9%
AZD1775
9%
Complete Remission
9%
Chronic Lymphocytic Leukemia
9%
COVID-19 Pandemic
9%
Multiple Myeloma
9%
B Cells
9%
Hematological Malignancies
9%
Clinical Trials
8%
Drug Sensitivity
8%
Intensive Chemotherapy
8%
Post-remission Therapy
8%
Risk Stratification
8%
Leukemia Risk
8%
Monoclonal Antibody
8%
DNA Damage
8%
Conventional Chemotherapy
8%
Salvage Therapy
7%
Oncoprotein
7%
FLT3 Internal Tandem Duplication
7%
Breakthrough COVID-19
7%
Primary Myelofibrosis
7%
Angioimmunoblastic
7%
Primary Hepatic Lymphoma
7%
Dysproteinemia
7%
Splenic Marginal Zone Lymphoma
7%
Mitotic Entry
7%
Longitudinal Tracking
7%
